Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet Thomas

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 15, 2018
Evidence- and consensus-based recommendations for the use of pegvaliase in adults with phenylketonuriaNicola Longo, David Dimmock, Harvey Levy, et al.
Molecular Genetics and Metabolism Reports|August 25, 2021
Use of pegvaliase in the management of phenylketonuria: Case series of early experience in US clinicsDarius Adams, Hans C Andersson, Heather Bausell, et al.
Journal of Clinical Pharmacology|November 21, 2024
Results of the ACTION-Galactosemia Kids Study to Evaluate the Effects of Govorestat in Pediatric Patients with Classic GalactosemiaEvan Bailey, Han Phan, Ayesha Ahmad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2019
miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C TrialGayathri Anandappa, Andrea Lampis, David Cunningham, et al.
Journal for Immunotherapy of Cancer|April 16, 2019
CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoidsReyes Gonzalez-Exposito, Maria Semiannikova, Beatrice Griffiths, et al.
Implementation Science Communications|April 10, 2021
Mixed-methods economic evaluation of the implementation of tobacco treatment programs in National Cancer Institute-designated cancer centersRamzi G Salloum, Heather D'Angelo, Ryan P Theis, et al.
Cancer Discovery|September 1, 2018
Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical TrialKhurum H Khan, David Cunningham, Benjamin Werner, et al.
Cancer Cell|July 10, 2019
Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal CancerAndrew Woolston, Khurum Khan, Georgia Spain, et al.
Orphanet Journal of Rare Diseases|August 21, 2015
Mudd's disease (MAT I/III deficiency): a survey of data for MAT1A homozygotes and compound heterozygotesYin-Hsiu Chien, Jose E Abdenur, Federico Baronio, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 15, 2018
Evidence- and consensus-based recommendations for the use of pegvaliase in adults with phenylketonuriaNicola Longo, David Dimmock, Harvey Levy, et al.
Molecular Genetics and Metabolism Reports|August 25, 2021
Use of pegvaliase in the management of phenylketonuria: Case series of early experience in US clinicsDarius Adams, Hans C Andersson, Heather Bausell, et al.
Journal of Clinical Pharmacology|November 21, 2024
Results of the ACTION-Galactosemia Kids Study to Evaluate the Effects of Govorestat in Pediatric Patients with Classic GalactosemiaEvan Bailey, Han Phan, Ayesha Ahmad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2019
miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C TrialGayathri Anandappa, Andrea Lampis, David Cunningham, et al.
Journal for Immunotherapy of Cancer|April 16, 2019
CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoidsReyes Gonzalez-Exposito, Maria Semiannikova, Beatrice Griffiths, et al.
Implementation Science Communications|April 10, 2021
Mixed-methods economic evaluation of the implementation of tobacco treatment programs in National Cancer Institute-designated cancer centersRamzi G Salloum, Heather D'Angelo, Ryan P Theis, et al.
Cancer Discovery|September 1, 2018
Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical TrialKhurum H Khan, David Cunningham, Benjamin Werner, et al.
Cancer Cell|July 10, 2019
Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal CancerAndrew Woolston, Khurum Khan, Georgia Spain, et al.
Orphanet Journal of Rare Diseases|August 21, 2015
Mudd's disease (MAT I/III deficiency): a survey of data for MAT1A homozygotes and compound heterozygotesYin-Hsiu Chien, Jose E Abdenur, Federico Baronio, et al.
Pageof 5